175 related articles for article (PubMed ID: 32822486)
1. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Ecker J; Thatikonda V; Sigismondo G; Selt F; Valinciute G; Oehme I; Müller C; Buhl JL; Ridinger J; Usta D; Qin N; van Tilburg CM; Herold-Mende C; Remke M; Sahm F; Westermann F; Kool M; Wechsler-Reya RJ; Chavez L; Krijgsveld J; Jäger N; Pfister SM; Witt O; Milde T
Neuro Oncol; 2021 Feb; 23(2):226-239. PubMed ID: 32822486
[TBL] [Abstract][Full Text] [Related]
2. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
[TBL] [Abstract][Full Text] [Related]
3. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
[TBL] [Abstract][Full Text] [Related]
4. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
[TBL] [Abstract][Full Text] [Related]
5. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
6. HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
Shofuda T; Kanemura Y
Neuro Oncol; 2021 Feb; 23(2):173-174. PubMed ID: 33394043
[No Abstract] [Full Text] [Related]
7. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
[TBL] [Abstract][Full Text] [Related]
8. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
9. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
10. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Marshall GM; Gherardi S; Xu N; Neiron Z; Trahair T; Scarlett CJ; Chang DK; Liu PY; Jankowski K; Iraci N; Haber M; Norris MD; Keating J; Sekyere E; Jonquieres G; Stossi F; Katzenellenbogen BS; Biankin AV; Perini G; Liu T
Oncogene; 2010 Nov; 29(44):5957-68. PubMed ID: 20697349
[TBL] [Abstract][Full Text] [Related]
12. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Hanigan CL; Van Engeland M; De Bruine AP; Wouters KA; Weijenberg MP; Eshleman JR; Herman JG
Gastroenterology; 2008 Nov; 135(5):1654-1664.e2. PubMed ID: 18834886
[TBL] [Abstract][Full Text] [Related]
13. Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.
Bharambe HS; Joshi A; Yogi K; Kazi S; Shirsat NV
Acta Neuropathol Commun; 2020 May; 8(1):70. PubMed ID: 32410663
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.
Adams CM; Eischen CM
Cell Death Differ; 2016 Aug; 23(8):1312-21. PubMed ID: 26915294
[TBL] [Abstract][Full Text] [Related]
15. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
[TBL] [Abstract][Full Text] [Related]
16. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.
Ashburner BP; Westerheide SD; Baldwin AS
Mol Cell Biol; 2001 Oct; 21(20):7065-77. PubMed ID: 11564889
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
Zika E; Greer SF; Zhu XS; Ting JP
Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
[TBL] [Abstract][Full Text] [Related]
18. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Sacco JJ; Kenyani J; Butt Z; Carter R; Chew HY; Cheeseman LP; Darling S; Denny M; Urbé S; Clague MJ; Coulson JM
Oncotarget; 2015 May; 6(15):13757-71. PubMed ID: 25970771
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Raghunathan S; Goyal RK; Patel BM
Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
[TBL] [Abstract][Full Text] [Related]
20. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
Zhou L; Picard D; Ra YS; Li M; Northcott PA; Hu Y; Stearns D; Hawkins C; Taylor MD; Rutka J; Der SD; Huang A
Cancer Res; 2010 Oct; 70(20):8199-210. PubMed ID: 20876797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
